白蛋白结合 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
==== Honorary appointments ==== Honorary General of the Swedish Army, 1888 Colonel-in-chief of the 1st King's Dragoon Guards, British Army, 25 March 1896 – 1914 Colonel-in-chief of the Kexholm Life Guards Grenadier Regiment, Russian Army, until 26 June 1914 Colonel-in-chief of the 12th Belgorod Lancer Regiment, Russian Army, until 26 June 1914 Colonel-in-chief of the 16th (Schleswig-Holstein) Hussars, German Army Colonel-in-chief of the 122nd (Emperor Francis Joseph of Austria, King of Hungary (4th Württemberg) Fusiliers Honorary Colonel of the 38th León Infantry Regiment, Spanish Army, 30 November 1905 Field Marshal of the British Army, 1 September 1903 – 1914
==== MeSH D12.776.964.775.750 – retroviridae proteins, oncogenic ==== MeSH D12.776.964.775.750.320 – fusion proteins, gag-onc MeSH D12.776.964.775.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.775.750.470 – gene products, rex MeSH D12.776.964.775.750.480 – gene products, tax MeSH D12.776.964.775.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.964.775.750.710 – oncogene protein p21(ras) MeSH D12.776.964.775.750.750 – oncogene protein p55(v-myc) MeSH D12.776.964.775.750.760 – oncogene protein pp60(v-src) MeSH D12.776.964.775.750.817 – oncogene protein v-maf MeSH D12.776.964.775.750.875 – oncogene proteins v-abl MeSH D12.776.964.775.750.882 – oncogene proteins v-erba MeSH D12.776.964.775.750.883 – oncogene proteins v-erbb MeSH D12.776.964.775.750.887 – oncogene proteins v-fos MeSH D12.776.964.775.750.900 – oncogene proteins v-mos MeSH D12.776.964.775.750.903 – oncogene proteins v-myb MeSH D12.776.964.775.750.920 – oncogene proteins v-raf MeSH D12.776.964.775.750.925 – oncogene proteins v-rel MeSH D12.776.964.775.750.935 – oncogene proteins v-sis
=== Heart and blood vessels === Bradycardia: Fentanyl decreases the heart rate by increasing vagal nerve tone in the brainstem, which increases the parasympathetic drive. Vasodilation: It also vasodilates arterial and venous blood vessels through a central mechanism, primarily by slowing down vasomotor centers in the brainstem. To a lesser extent, it does this by directly affecting blood vessels. This is much more profound in patients who have an already increased sympathetic drive, like patients who have high blood pressure or congestive heart failure. It does not affect the contractility of the heart when regular doses are administered.
Sources: en.wikipedia.org
89Sr is the active ingredient in Metastron, a radiopharmaceutical used for bone pain secondary to metastatic bone cancer. The strontium is processed like calcium by the body, preferentially incorporating it into bone at sites of increased osteogenesis. This localization focuses the radiation exposure on the cancerous lesion. 90Sr has been used as a power source for radioisotope thermoelectric generators (RTGs). 90Sr produces approximately 0.93 watts of heat per gram (it is lower for the form of 90Sr used in RTGs, which is strontium fluoride). However, 90Sr has one third the lifetime and a lower density than 238Pu, another RTG fuel. The main advantage of 90Sr is that it is significantly cheaper than 238Pu and is found in nuclear waste. The latter must be prepared by irradiating 237Np with neutrons then separating the modest amounts of 238Pu. The principal disadvantage of 90Sr is the high energy beta particles produce Bremsstrahlung as they encounter nuclei of other nearby heavy atoms such as adjacent strontium. This is mostly in the range of X-rays. Thus strong beta emitters also emit significant secondary X-rays in most cases. This requires significant shielding measures which complicates the design of RTGs using 90Sr. The Soviet Union deployed nearly 1000 of these RTGs on its northern coast as a power source for lighthouses and meteorology stations.
Vasodilation and increased permeability of capillaries are a result of both H1 and H2 receptor types. Stimulation of histamine activates a histamine (H2)-sensitive adenylate cyclase of oxyntic cells, and there is a rapid increase in cellular [cAMP] that is involved in activation of H+ transport and other associated changes of oxyntic cells. Antihistamine drugs act by blocking histamine action at nerve endings. Cromoglicate-based drugs (sodium cromoglicate, nedocromil) block a calcium channel essential for mast cell degranulation, stabilizing the cell and preventing release of histamine and related mediators. Leukotriene antagonists (such as montelukast and zafirlukast) block the action of leukotriene mediators.
Historians Robert Friedel and Paul Israel list inventors of incandescent lamps prior to Joseph Swan and Thomas Edison of General Electric. They conclude that Edison's version was the first practical implementation, able to outstrip the others because of a combination of four factors: an effective incandescent material; a vacuum higher than other implementations; a high resistance that made power distribution from a centralized source economically viable, and the development of the associated components required for a large-scale lighting system. However, Joseph Swan's incandescent light bulb pre-dated Edison's and was sufficiently practical that it was actually installed and in daily use in London in 1881. Historian Thomas Hughes has attributed Edison's business success to his development of an entire, integrated system of electric lighting.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。